Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2008 1
2011 1
2012 2
2013 2
2014 3
2015 1
2016 3
2017 6
2018 4
2019 3
2020 5
2021 10
2022 8
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K, Matsushita K, Iwasaki T, Sakaino N, Sakanashi T, Hirayama K, Kurokawa H, Kikuta K, Yamamoto N, Sato K, Tokitsu T, Taguchi T, Shiosakai K, Sugimoto K, Tsujita K; ESES-LVH investigators. Yamamoto E, et al. Among authors: sugimoto k. Adv Ther. 2024 Mar;41(3):1284-1303. doi: 10.1007/s12325-024-02780-6. Epub 2024 Feb 4. Adv Ther. 2024. PMID: 38310194 Free PMC article. Clinical Trial.
Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, Fukui T, Hatta T, Iwasaki A, Ishii H, Sugiura T, Taguchi T, Tanabe A, Sugimoto K, Shimosawa T; ENaK investigators. Katsuya T, et al. Among authors: sugimoto k. Hypertens Res. 2024 Apr;47(4):835-848. doi: 10.1038/s41440-023-01519-0. Epub 2024 Jan 11. Hypertens Res. 2024. PMID: 38212366 Free PMC article.
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, Masuda I, Sekimura N, Yamamoto K, Sato A, Komatsu M, Taguchi T, Shiosakai K, Sugimoto K, Kuwahara K. Motoki H, et al. Among authors: sugimoto k. Adv Ther. 2023 Nov;40(11):5055-5075. doi: 10.1007/s12325-023-02633-8. Epub 2023 Sep 21. Adv Ther. 2023. PMID: 37733211 Free PMC article.
Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
Kario K, Ohishi M, Katsuya T, Taguchi T, Tanabe A, Sugimoto K, Shimosawa T. Kario K, et al. Among authors: sugimoto k. J Clin Hypertens (Greenwich). 2023 Sep;25(9):861-867. doi: 10.1111/jch.14705. Epub 2023 Aug 7. J Clin Hypertens (Greenwich). 2023. PMID: 37551054 Free PMC article. Clinical Trial.
SPON1 is an independent prognostic biomarker for ovarian cancer.
Miyakawa R, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Kobayashi Y, Furukawa S, Honda T, Watanabe T, Asano S, Soeda S, Hashimoto Y, Fujimori K, Chiba H. Miyakawa R, et al. Among authors: sugimoto k. J Ovarian Res. 2023 May 13;16(1):95. doi: 10.1186/s13048-023-01180-8. J Ovarian Res. 2023. PMID: 37179355 Free PMC article.
Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, Takahashi N, Asakura T, Shiraiwa T, Yoshida T, Kaneshiro M, Taguchi T, Shiosakai K, Sugimoto K. Kario K, et al. Among authors: sugimoto k. Hypertens Res. 2023 Jul;46(7):1782-1794. doi: 10.1038/s41440-023-01292-0. Epub 2023 May 12. Hypertens Res. 2023. PMID: 37173430 Free PMC article.
57 results